Related Tags >> lorcaserin obesity Vivus Orexigen Therapeutics

Arena Pharmaceuticals News

Most Popular Arena Pharmaceuticals Story

Orexigen surges on FDA trial pact for troubled weight loss drug

February 7, 2012 — 10:24am ET | By John Carroll

Shares of Orexigen Therapeutics ($OREX) shot up 18% yesterday after the biotech laid out a special protocol assessment pact with the FDA, detailing the design of a big new safety study of its weight Read more...

Arena Pharmaceuticals Press Releases

Obesity Drug Candidates From Arena Pharmaceuticals and Vivus Look to Make Big Splash in 2012
S1P1 Lead Compounds, AMG 369 and AMG 277, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
FibroGen Appoints Michael Martinelli, Ph.D., Vice President of Technical Development
Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Weight Loss

Latest Headlines

Orexigen surges on FDA trial pact for troubled weight loss drug
February 7, 2012
Arena Pharma raises $33M
January 11, 2012
Arena shares shine, briefly, as it presents its case for obesity drug
January 4, 2012
Can Arena's latest safety study help satisfy FDA's cancer worries?
August 2, 2011
Arena stands by plan to short-circuit rat study for lorcaserin
May 11, 2011
Arena CFO Hoffman departs
February 11, 2011
Arena ($ARNA) shares slide after it slashes staff, outlines FDA's lorcaserin demands
January 27, 2011
Arena maps out its one-year plan for lorcaserin
December 22, 2010
Orexigen shares skyrocket after FDA panel endorses obesity drug
December 7, 2010
Orexigen ($OREX) braces for a brutal panel review
November 30, 2010
Arena ($ARNA) touts new obesity data as it campaigns for quick OK
November 9, 2010
J&J ($JNJ) drops Arena ($ARNA) diabetes drug pact
November 5, 2010
Analysts take on obesity drugs turns grim after lorcaserin CRL
October 26, 2010
After FDA's ARNA decision, what's next for obesity drugs?
October 25, 2010
Timeline: A look back at Arena's lorcaserin
October 25, 2010
FDA throws up a tricky roadblock for Arena's lorcaserin
October 24, 2010
FDA responds to outraged Arena investors
October 22, 2010
Loyal Arena investors battling for diet drug approval
October 14, 2010
Advisory panel rejections carry the greatest clout at the FDA
October 13, 2010
Lawsuits start to pile up in wake of Arena setback
September 23, 2010

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events